Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
July 27 2020 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, will report second quarter 2020
financial results after the Nasdaq Global Market close on Monday,
August 10, 2020.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead
program is edasalonexent, an NF-kB inhibitor in Phase 3 development
for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our Phase 3 PolarisDMD trial,
please visit www.catabasis.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200727005032/en/
Investor and Media Contact Andrea
Matthews Catabasis Pharmaceuticals, Inc. T: (617) 349-1971
amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Sep 2023 to Sep 2024